CSL to invest $117m in Varmx.

CSL, a biotechnology company, agreed to invest $117m in VarmX, a biotech firm. “The collaboration with CSL represents a transformative step for VarmX. By securing full funding for the registrational trial, product development, CMC and pre-launch activities, we are well positioned to bring VMX-C001 to patients. We are proud to partner with CSL, whose expertise and global reach will be invaluable as we move forward,” John Glasspool, VarmX Chief Executive Officer.